Diligence memo · auto-generated · as of July 2, 2026

Topica Pharmaceuticals Inc

Topica Pharmaceuticals Inc looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Topica Pharmaceuticals Inc operates in Pharmaceuticals, based in LOS ALTOS.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Topica Pharmaceuticals Inc has raised $52M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $32M on 2011-10-17.

Most recent recorded round closed around 2011-10-17.

Valuation (modeled)modeled

Provath models Topica Pharmaceuticals Inc at approximately $1.1B (range $66M–$4.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.45× the median modeled value of Series B Pharmaceuticals companies in 2010–2012 (47 peers) — value vs value, same stage and era. Within the normal band (145% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 14.7 yr ago; this sector typically re-raises about every 13 months.

Silent for over 3× the sector's normal cadence.

The last round was 1.6× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 82% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 89% of those peers.

Closest niche peers: Celator Pharmaceuticals Inc, Kythera Biopharmaceuticals Inc, Palatin Technologies Inc, Pernix Therapeutics Holdings, Inc., CEBIX Inc.

Peoplefiled

11 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.